Synergistic action between a synthetic cannabinoid compound and tramadol in neuropathic pain rats
References
- 1. A. Mohammadkhani and S. L. Borgland, Cellular and behavioral basis of cannabinoid and opioid interactions: Implications for opioid dependence and withdrawal, J. Neurosci. Res. 100 (2022) 278–296; https://doi.org/10.1002/jnr.24770
- 2. M. Ghonghadze, K. Pachkoria, M. Okujava, N. Antelava and N. Gongadze, Endocannabinoids receptors mediated central and peripheral effects, Georgian Med. News 298 (2020) 137–143.
- 3. E. E. Bagley and S. L. Ingram, Endogenous opioid peptides in the descending pain modulatory circuit, Neuropharmacology 173 (2020) Article ID 108131; https://doi.org/10.1016/j.neuropharm.2020.108131
- 4. G. Corder, D. D. Castro, M. R. Bruchas and G. Scherrer, Endogenous and exogenous opioids in pain, Annu. Rev. Neurosci. 41 (2018) 453–473; https://doi.org/10.1146/annurev-neuro-080317-061522
- 5. S. Narouze, Antinociception mechanisms of action of cannabinoid-based medicine: an overview for anesthesiologists and pain physicians, Reg. Anesth. Pain Med. 46(3) (2021) 240–250; https://doi.org/10.1136/rapm-2020-102114
- 6. W. Fujita, I. Gomes and L. A. Devi, Revolution in GPCR signaling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10, Br. J. Pharmacol. 171(18) (2014) 4155–4176; https://doi.org/10.1111/bph.12798
- 7. S. Sierra, A. Gupta, I. Gomes, M. Fowkes, A. Ram, E. N. Bobeck, and L. A. Devi, Targeting cannabinoid 1 and delta-opioid receptor heteromers alleviates chemotherapy-induced neuropathic pain, ACS Pharmacol. Transl. Sci. 2 (2019) 219–229; https://doi.org/10.1021/acsptsci.9b00008
- 8. M. M. Ibrahim, F. Porreca, J. Lai, P. J. Albrecht, F. L. Rice, A. Khodorova, G. Davar, A. Makriyannis, T. W. Vanderah, H. P. Mata and T. P. Malan, CB2 cannabinoid receptor activation produces anti-nociception by stimulating peripheral release of endogenous opioids, Proc. Natl. Acad. Sci. USA 102(8) (2005) 3093–3098; https://doi.org/10.1073/pnas.0409888102
- 9. S. P. Welch and D. L. Stevens, Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice, J. Pharmacol. Exp. Ther. 262(1) (1992) 10–18.
- 10. F. L. Smith, D. Cichewicz, Z. L. Martin and S. P. Welch, The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol, Pharmacol. Biochem. Behav. 60(2) (1998) 559–566; https://doi.org/10.1016/s0091-3057(98)00012-4
- 11. O. Gunduz, H. C. Karadag and A. Ulugol, Synergistic anti-allodynic effects of nociceptin/orphanin FQ and cannabinoid systems in neuropathic mice, Pharmacol. Biochem. Behav. 99(4) (2011) 540–544; https://doi.org/10.1016/j.pbb.2011.05.029
- 12. J. M. Vigil, S. S. Stith, I. M. Adams and A. P. Reeve, Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study, PLoS One 12 (2017) e0187795 (13 pages); https://doi.org/10.1371/journal.pone.0187795
- 13. G. N. Quiñonez-Bastidas, O. Palomino-Hernández, M. López-Ortíz, H. I. Rocha-González, G. M. González-Anduaga, I. Regla and A. Navarrete, Antiallodynic effect of PhAR-DBH-Me involves cannabinoid and TRPV1 receptors, Pharmacol. Res. Perspect. 8 (2020) e00663 (12 pages); https://doi.org/10.1002/prp2.663
- 14. M. Lopez-Ortiz, A. Herrera-Solis, A. Luviano-Jardon, N. Reyes-Prieto, I. Castillo, I. Monsalvo, P. Demare, M. Méndez-Díaz, I. Regla and O. Prospéro-García, Chemoenzymatic synthesis and cannabinoid activity of a new diazabicyclic amide of phenylacetylricinoleic acid, Bioorg. Med. Chem. Lett. 20(11) (2010) 3231–3234; https://doi.org/10.1016/j.bmcl.2010.04.074
- 15. S. H. Kim and J. M. Chung, An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat, Pain 50 (1992) 355–363; https://doi.org/10.1016/0304-3959(92)90041-9
- 16. N. Authier, J. P. Gillet, J. Fialip, A. Eschalier and F. Coudore, An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections, Exp. Neurol. 182(1) (2003) 12–20; https://doi.org/10.1016/s0014-4886(03)00003-7
- 17. S. R. Chaplan, F. W. Bach, J. W. Pogrel, J. M. Chung and T. L. Yaksh, Quantitative assessment of tactile allodynia in the rat paw, J. Neurosci. Meth. 53(1) (1994) 55–63; https://doi.org/10.1016/0165-0270(94)90144-9
- 18. R. J. Tallarida, Drug Synergism and Dose-Effect Data Analysis, in Drug Synergism and Dose-Effect Data Analysis, 1st ed., Chapman and Hall/CRC, New York 2000.
- 19. J. Balderas-López, A. Navarrete and A. Alfaro, Graded Dose-Response Curves, in Pharmacometrics, 1st ed., Universidad Nacional Autonóma de México, Mexico City 2017.
- 20. S. Goutelle, M. Maurin, F. Rougier, X. Barbaut, L. Bourguignon, M. Ducher and P. Maire, The Hill equation: a review of its capabilities in pharmacological modelling, Fundam. Clin. Pharmacol. 22(6) (2008) 633–648; https://doi.org/10.1111/j.1472-8206.2008.00633.x
- 21. S. de J. Acosta-Cota, E. M. Aguilar-Medina, R. Ramos-Payána, J. G. Rendón Maldonado, J. G. Romero-Quintana, J. Montes-Avila, J. I. Sarmiento-Sánchez, C. G. Plazas-Guerrero, M. J.Vergara-Jiménez, A. Sánchez-López, D. Centurión and U. Osuna-Martínez, Therapeutic effect of treatment with metformin and/or 4-hydroxychalcone in male Wistar rats with nonalcoholic fatty liver disease, Eur. J. Pharmacol. 863 (2019) Article ID 172699 (14 pages); https://doi.org/10.1016/j.ejphar.2019.172699
- 22. R. A. Gibson, J.-A Lim, S. J. Choi, L. Flores, L. Clinton, D. Bali, S. Young, A. Asokan, B. Sun and P. S. Kishnani, Characterization of liver GSD IX g2 pathophysiology in a novel Phkg2−/− mouse model, Mol. Genet. Metab. 133(3) (2021) 269–276; https://doi.org/10.1016/j.ymgme.2021.05.008
- 23. N. P. Kazantzis, S. L. Casey, P. W. Seow, V. A. Mitchell and C. W. Vaughan, Opioid and cannabinoid synergy in a mouse neuropathic pain model, Br. J. Pharmacol. 173(16) (2016) 2521–2531; https://doi.org/10.1111/bph.13534
- 24. M. Déciga-Campos, P. M. Ramírez-Marín and F. J. López-Muñoz, Synergistic antinociceptive interaction between palmitoylethanolamide and tramadol in the mouse formalin test, Eur. J. Pharmacol. 765 (2015) 68–74; https://doi.org/10.1016/j.ejphar.2015.08.025
- 25. L. Roulet, V. Rollason, J. Desmeules and V. Piguet, Tapentadol versus tramadol: A narrative and comparative review of their pharmacological, efficacy and safety profiles in adult patients, Drugs 81 (2021) 1257–1272; https://doi.org/10.1007/s40265-021-01515-z
- 26. N. T. Snider, M. J. Sikora, C. Sridar, T. J. Feuerstein, J. M. Rae and P. F. Hollenberg, The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6, J. Pharmacol. Exp. Ther. 327(2) (2008) 538–545; https://doi.org/10.1124/jpet.108.141796
- 27. N. T. Snider, J. A. Nast, L. A. Tesmer and P. F. Hollenberg, A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist, Mol. Pharmacol. 75(4) (2009) 965–972; https://doi.org/10.1124/mol.108.053439
- 28. M. Pratt-Hyatt, H. Zhang, N. T. Snider and P. F. Hollenberg, Effects of a commonly occurring genetic polymorphism of human CYP3A4 (I118V) on the metabolism of anandamide, Drug Metab. Dispos. 38(11) (2010) 2075–2082; https://doi.org/10.1124/dmd.110.033712
- 29. M. Vázquez, N. Guevara, C. Maldonado, P. C. Guido and P. Schaiquevich, Potential pharmaco-kinetic drug-drug interactions between cannabinoids and drugs used for chronic pain, Biomed. Res. Int. 2020 (2020) Article ID 3902740 (9 pages); https://doi.org/10.1155/2020/3902740
- 30. J. Guindon, Y. Lai, S. M. Takacs, H. B. Bradshaw and A. G. Hohmann, Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment, Pharmacol. Res. 67(1) (2013) 94–109; https://doi.org/10.1016/j.phrs.2012.10.013
- 31. H. L. Blanton, J. Brelsfoard, N. DeTurk, K. Pruitt, M. Narasimhan, D. J. Morgan and J. Guindon, Cannabinoids: Current and future options to treat chronic and chemotherapy-induced neuropathic pain, Drugs 79 (2019) 969–995; https://doi.org/10.1007/s40265-019-01132-x
- 32. D. da Fonseca Pacheco, A. Klein, A. P. de Castro, C. M. da Fonseca Pacheco, J. N. de Francischi and I. D. G. Duarte, The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa--opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors, Br. J. Pharmacol. 154(5) (2008) 1143–1149; https://doi.org/10.1038/bjp.2008.175
- 33. B. Wiese and A. R. Wilson-Poe, Emerging evidence for cannabis’ role in opioid use disorder, Cannabis Cannabinoid Res. 3(1) (2018) 179–189; https://doi.org/10.1089/can.2018.0022
- 34. N. Petejova and A. Martinek, Acute kidney injury following acute pancreatitis: A review, Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 157(2) (2013) 105–113; https://doi.org/10.5507/bp.2013.048
- 35. J. Zaias, M. Mineau, C. Cray, D. Yoon and N. H. Altman, Reference values for serum proteins of common laboratory rodent strains, J. Am. Assoc. Lab. Anim. Sci. 48(4) (2009) 387–390.
- 36. J. S. Hochman and N. Q. Brill, Chronic marihuana usage and liver function, Lancet 298(7728) (1971) 818–819; https://doi.org/10.1016/s0140-6736(71)92771-1
- 37. L. E. Ewing, C. M. Skinner, C. M. Quick, S. Kennon-McGill, M. R. McGill, L. A. Walker, M. A. ElSohly, B. J. Gurley and I. Koturbash, Hepatotoxicity of a cannabidiol-rich cannabis extract in the mouse model, Molecules 24(9) (2019) Article ID 1694 (17 pages); https://doi.org/10.3390/molecules24091694
- 38. Y.-C. Hsu, C.-C. Lei, Y.-H. Shih, C. Ho and C.-L. Lin, Induction of proteinuria by cannabinoid receptors 1 signaling activation in CB1 transgenic mice, Am. J. Med. Sci. 349(2) (2015) 162–168; https://doi.org/10.1097/MAJ.0000000000000352
- 39. E. C. Morais Rateke, C. Matiollo, E. Q. de Andrade Moura, M. Andrigueti, C. Maccali, J. S. Fonseca, S. M. F. Canova, J. L. Narciso-Schiavon and L. L. Schiavon, Low sodium to potassium ratio in spot urine sample is associated with progression to acute kidney injury and mortality in hospitalized patients with cirrhosis, Dig. Liver Dis. 53(9) (2021) 1159–1166; https://doi.org/10.1016/j.dld.2020.12.117
- 40. M. Boada, A. Pippo, M. Rodriguez-Milhomens, V. González, R. Higgie, V. Mérola, J. M. Carissi and R. Silvariño, Hiperpotasemia severa en emergencia: Manifestaciones clínicas y manejo terapéutico a propósito de tres casos [Severe hyperkalemia in emergency: Clinical manifestations and therapeutic management of three cases], Arch. Med. Int. 34 (2012) 91–94.
- 41. Y. Koura, A. Ichihara, Y. Tada, Y. Kaneshiro, H. Okada, C. J. Temm, M. Hayashi and T. Saruta, Anandamide decreases glomerular filtration rate through predominant vasodilation of efferent arterioles in rat kidneys, J. Am. Soc. Nephrol. 15(6) (2004) 1488–1494; https://doi.org/10.1097/01.asn.0000130561.82631.bc
- 42. J. S. Kim, J. Y. Son, K. S. Kim, H. J. Lim, M.-Y. Ahn, S. J. Kwack, Y.-M. Kim, K. Y. Lee, J. Lee, B. M. Lee and H. S. Kim, Hepatic damage exacerbates cisplatin-induced acute kidney injury in Sprague--Dawley rats, J. Toxicol. Environ. Health A 81(11) (2018) 397–407; https://doi.org/10.1080/15287394.2018.1451179
- 43. C. J. Lucas, P. Galettis and J. Schneider, The pharmacokinetics and the pharmacodynamics of cannabinoids, Br. J. Clin. Pharmacol. 84(11) (2018) 2477–2482; https://doi.org/10.1111/bcp.13710
- 44. P. Pacher and R. Mechoulam, Is lipid signaling through cannabinoid 2 receptors part of a protective system?, Prog. Lipid. Res. 50 (2011) 193–211; https://doi.org/10.1016/j.plipres.2011.01.001
- 45. M. Rajesh, H. Pan, P. Mukhopadhyay, S. Bátkai, D. Osei-Hyiaman, G. Haskó, L. Liaudet, B. Gao and P. Pacher, Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis, J. Leukoc. Biol. 82(6) (2007) 1382–1389; https://doi.org/10.1189/jlb.0307180
- 46. J. S. Richter, V. Quenardelle, O. Rouyer, J. S. Raul, R. Beaujeux, B. Gény and V. Wolff, A systematic review of the complex effects of cannabinoids on cerebral and peripheral circulation in animal models, Front. Physiol. 9 (2018) Article ID 622 (13 pages); https://doi.org/10.3389/fphys.2018.00622
- 47. P. Pacher, S. Steffens, G. Haskó, T. H. Schindler and G. Kunos, Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly, Nat. Rev. Cardiol. 15 (2018) 151–166; https://doi.org/10.1038/nrcardio.2017.130
- 48. J. A. Wagner, K. Varga, E. F. Ellis, B. A. Rzigalinski, B. R. Martin and G. Kunos, Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock, Nature 390(6659) (1997) 518–521; https://doi.org/10.1038/37371
Language: English
Page range: 509 - 527
Accepted on: Apr 21, 2022
Published on: Oct 18, 2022
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2022 Geovanna Nallely Quiñonez-Bastidas, Ulises Osuna-Martínez, Ana Laura Reda-Licea, Manuel López-Ortíz, Ignacio Regla, Andrés Navarrete, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.